References
- Aster JC, DeAngelo DJ. (2011): Chapter 21: Acute Leukemias. In: Pathophysiology of blood disorders, eds Bunn H, Aster J, The McGraw-Hill Companies, Inc., New York, pp. 244–259.
- Rytting ME, ed. (2013): Acute leukemia. Merck Manual Professional. Merck Sharp & Dohme Corp., Whitehouse Station.
- National Cancer Institute Age-Adjusted and Age-Specific SEER Cancer Incidence Rates, 2014–2018. [(accessed on 18 April 2021)]; Available online
- Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet 371, 1030–1043 (2008).
- Pui CH, Carroll WL, Meshinchi S, Arceci RJ: Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 29, 551–565 (2011).
- Inaba H., Greaves M., Mullighan C.G. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–1955. doi: 10.1016/S0140-6736(12)62187-4.
- Malard F., Mohty M. Acute lymphoblasti leukaemia. Lancet. 2020; 395: 1146–1162. doi: 10.1016/S0140-6736(19)33018-1
- Hunger S.P., Mullighan C.G. Acute Lymphoblastic Leukemia in Children. N. Engl. J. Med. 2015;373:1541–1552. doi: 10.1056/NEJMra1400972.
- Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, Jonsson OG, Lausen B, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011; 29: 310–5. doi: 10.1200/JCO.2010.30.6829
- Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122:170–8. doi: 10.1182/blood-2013-03-491621.
- Kosmidis S, Baka M, Bouhoutsou D, et al. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL. Pediatr Blood Cancer.2008; 50(3): 528–32.
- Alanko S, Salmi TT, Pelliniemi TT. Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pedi atr HematolOncol.1994;11(3): 281–92.
- Eyrich M, Wiegering V, Lim A, Schrauder A, Winkler B, Schlegel PG. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia: a prospective study of 20 paediatric patients. Br J Haematol.2009; 147(3): 360–70.
- van Tilburg CM, van der Velden VH, Sanders EA, et al. Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: impact on lymphocyte compartment composition. LeukRes. 2011; 35(4): 484–91.
- Pietras W, Chaber R, Pela H, Trybucka K, Chybicka A. The recovery of immune system parameters in children following lymphoblastic leukemia therapy: preliminary report. Adv Clin Exp Med.2014; 23(1): 97–102.
- Rudant J, Lightfoot T, Urayama K, Petridou E, Dockerty J, Magnani C, Milne E, Spector LG, Ashton LJ, Dessypris N, Kang AY, Miller M, Rondelli R, Simpson J, Stiakaki E, Orsi L, Roman E, Metayer C, Infante-Rivard C, Clavel J: Childhood acute lymphoblastic leukemia and indicators of early immune stimulation: A childhood leukemia international consortium study. Am J Epidemiol 181, 549–562 (2015).
- Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017; 188: 333–341.
- Cario G, Rhein P, Mitlöhner R, Zimmermann M, Bandapalli OR, Romey R, Moericke A, Ludwig WD, Ratei R, Muckenthaler MU, Kulozik AE, Schrappe M, Stanulla M, Karawajew L. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2014 Jan;99(1):103-10. doi: 10.3324/haematol.2013.090225. Epub 2013 Aug 2. PMID: 23911702; PMCID: PMC4007934.
- WuCP,QingX,WuCY,ZhuH,ZhouHY.Immunophenotypeandincreased presence of CD4(+) CD25(+) regulatory T cells in patients with acute lymphoblastic leukemia. Oncol Lett. (2012) 3: 421–4. doi: 10.3892/ol.2011.499
- Salem ML, El-Shanshory MR, Abdou SH, Attia MS, Sobhy SM, Zidan MF, et al. Chemotherapy alters the increased numbers of myeloid derived suppressor and regulatory T cells in children with acute lymphoblastic leukemia. ImmunopharmacolImmunotoxicol. (2018) 40: 158–67. doi: 10.1080/08923973.2018.1424897
- van Tilburg CM, van der Velden VH, Sanders EA, Wolfs TF, Gaiser JF, de Haas V, et al. Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: impact on lymphocyte compartment composition. Leuk Res. (2011) 35: 484–91. doi: 10.1016/j.leukres.2010. 10.005
- Das RK, Vernau L, Grupp SA, Barrett DM. Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. (2019) 9: 492–9. doi: 10.1158/2159-8290.CD-18-1314
- Rheinländer A, Schraven B, Bommhardt U. CD45 in human physiology and clinical medicine. Immunol Lett. 2018 Apr; 196: 22–32. doi: 10.1016/j.imlet.2018.01.009. Epub 2018 Jan 31. PMID: 29366662.
- Ballo O, Tarazzit I, Stratmann J, Reinheimer C, Hogardt M, Wichelhaus TA, et al. Colonization With Multidrug Resistant Organisms Determines the Clinical Course of Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy. PloS One (2019) 14(1): e0210991. doi: 10.1371/journal.pone.0210991
- Chinen J, Shearer WT. Secondary Immunodeficiencies, Including HIV Infection. J Allergy Clin Immunol (2010) 125(2 Suppl.):S195–203. doi: 10.1016/j.jaci.2009.08.040
- Na IK, Buckland M, Agostini C, et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol. 2019; 102(6): 447–456.
- Joanna Zawitkowska, Katarzyna Drabko, Anna Szmydki-Baran, Agnieszka Zaucha-Prażmo, Monika Lejman, Krzysztof Czyżewski, Infectious profile in children with ALL during chemotherapy: A report of study group for infections, J Infect Chemother. 2019 Oct;25(10): 774–779. doi: 10.1016/j.jiac.2019.04.005. Epub 2019 May 14.
- Stephen Jolles, Mauricette Michallet,Carlo Agostini, Michael Albert,David Edgar,Roberto Ria,Livio Trentin,Elisabeth Clodi,Vincent Lévy. AN INTERNATIONAL DELPHI CONSENSUS BUILDING APPROACH TO PATIENT ASSESSMENT AND USE OF IMMUNOGLOBULIN TREATMENT FOR SECONDARY IMMUNE DEFICIENCIES IN HEMATOLOGICAL MALIGNANCY. EHA Library. Albert M. 06/12/20; 297829; PB1913
- C L Mackall, T A Fleisher et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer, Blood. 1994 Oct 1; 84(7): 2221–8.